{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T01:16:22Z","timestamp":1775610982959,"version":"3.50.1"},"reference-count":117,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AG056614"],"award-info":[{"award-number":["R01AG056614"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K23GM129630"],"award-info":[{"award-number":["K23GM129630"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD), the most common form of senile dementia, is poised to place an even greater societal and healthcare burden as the population ages. With few treatment options for the symptomatic relief of the disease and its unknown etiopathology, more research into AD is urgently needed. Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Using microdosing, psychedelic drugs may prove to help combat this devastating disease by eliciting psychiatric benefits via acting through various mechanisms of action such as serotonin and dopamine pathways. Herein, we review the studied benefits of a few psychedelic compounds that may show promise in treating AD and attenuating its related depressive symptoms. We used the listed keywords to search through PubMed for relevant preclinical, clinical research, and review articles. The putative mechanism of action (MOA) for psychedelics is that they act mainly as serotonin receptor agonists and induce potential beneficial effects for treating AD and related depression.<\/jats:p>","DOI":"10.3390\/ijms241512513","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T06:37:31Z","timestamp":1691390251000},"page":"12513","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Brief Review on the Potential of Psychedelics for Treating Alzheimer\u2019s Disease and Related Depression"],"prefix":"10.3390","volume":"24","author":[{"given":"Alexander","family":"Pilozzi","sequence":"first","affiliation":[{"name":"Neurochemistry Laboratory, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1703-4181","authenticated-orcid":false,"given":"Simmie","family":"Foster","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA"},{"name":"Depression Clinical & Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-5860","authenticated-orcid":false,"given":"David","family":"Mischoulon","sequence":"additional","affiliation":[{"name":"Depression Clinical & Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Fava","sequence":"additional","affiliation":[{"name":"Depression Clinical & Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-1901","authenticated-orcid":false,"given":"Xudong","family":"Huang","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1017\/S1355617703910101","article-title":"What does the WMS-III tell us about memory changes with normal aging?","volume":"9","author":"Haaland","year":"2003","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1037\/0894-4105.22.5.638","article-title":"Age-related differences in cognition: The role of distraction control","volume":"22","author":"Darowski","year":"2008","journal-title":"Neuropsychology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1037\/0278-7393.15.3.507","article-title":"Effects of adult age and working memory on reasoning and spatial abilities","volume":"15","author":"Salthouse","year":"1989","journal-title":"J. Exp. Psychol. Learn. Mem. Cogn."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1212\/01.WNL.0000034176.07159.F8","article-title":"Incidence and outcome of mild cognitive impairment in a population-based prospective cohort","volume":"59","author":"Larrieu","year":"2002","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1212\/WNL.0000000000004015","article-title":"Effects of MCI subtype and reversion on progression to dementia in a community sample","volume":"88","author":"Aerts","year":"2017","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"(2022). 2022 Alzheimer\u2019s disease facts and figures. Alzheimers Dement., 18, 700\u2013789.","DOI":"10.1002\/alz.12638"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","article-title":"A resurrection of aducanumab for Alzheimer\u2019s disease","volume":"19","author":"Schneider","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_8","first-page":"208","article-title":"Drugs for Alzheimer\u2019s disease: Are they effective?","volume":"35","author":"Casey","year":"2010","journal-title":"Pharm. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: Past, present, and future","volume":"42","author":"Goodwin","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: More questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0006-3223(02)01348-3","article-title":"Depression in Alzheimer\u2019s disease: Overview and treatment","volume":"52","author":"Lyketsos","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.biopsych.2005.05.001","article-title":"Mood disorders in the medically ill: Scientific review and recommendations","volume":"58","author":"Evans","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/YCO.0b013e32834bb9d4","article-title":"Depression in dementia: Epidemiology, mechanisms, and treatment","volume":"24","author":"Enache","year":"2011","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0165-0327(95)00072-0","article-title":"The prevalence, associations and symptoms of depression amongst dementia sufferers","volume":"36","author":"Ballard","year":"1996","journal-title":"J. Affect. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/alz.12390","article-title":"Suicide risk in first year after dementia diagnosis in older adults","volume":"18","author":"Schmutte","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1590\/1980-57642016dn11-030015","article-title":"Disease awareness may increase risk of suicide in young onset dementia: A case report","volume":"11","author":"Baptista","year":"2017","journal-title":"Dement. Neuropsychol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fnins.2018.00371","article-title":"A complex relationship between suicide, dementia, and amyloid: A narrative review","volume":"12","author":"Conejero","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"P610","DOI":"10.1016\/j.jalz.2014.05.1036","article-title":"P2-356: Predictive Testing for alzheimer\u2019s disease: Suicidal ideation among healthy participants","volume":"10","author":"Caselli","year":"2014","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/jnnp.2004.052795","article-title":"On the overlap between apathy and depression in dementia","volume":"76","author":"Starkstein","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/00019442-200509000-00009","article-title":"Specificity of symptoms of depression in Alzheimer disease: A longitudinal analysis","volume":"13","author":"Starkstein","year":"2005","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1176\/jnp.9.4.556","article-title":"Major and minor depression in Alzheimer\u2019s disease: Prevalence and impact","volume":"9","author":"Lyketsos","year":"1997","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"113294","DOI":"10.1016\/j.psychres.2020.113294","article-title":"High depression and anxiety in people with Alzheimer\u2019s disease living in retirement homes during the covid-19 crisis","volume":"291","author":"Altintas","year":"2020","journal-title":"Psychiatry Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2009.10.022","article-title":"Depression and Alzheimer\u2019s disease: Neurobiological links and common pharmacological targets","volume":"626","author":"Caraci","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1176\/ajp.146.3.350","article-title":"Depression and Alzheimer\u2019s disease","volume":"146","author":"Rovner","year":"1989","journal-title":"Am. J. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3233\/JAD-161247","article-title":"Efficacy of antidepressants for depression in Alzheimer\u2019s disease: Systematic review and meta-analysis","volume":"58","author":"Orgeta","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2990.2000.00254.x","article-title":"Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer\u2019s disease prospectively assessed for behavioural changes","volume":"26","author":"Chen","year":"2000","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1176\/appi.ajp.161.6.1096","article-title":"Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer\u2019s disease with and without depression","volume":"161","author":"Hendricksen","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13195-019-0491-2","article-title":"Neuroinflammation and amyloid-beta 40 are associated with reduced serotonin transporter (SERT) activity in a transgenic model of familial Alzheimer\u2019s disease","volume":"11","author":"Metaxas","year":"2019","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"14968","DOI":"10.1073\/pnas.1107411108","article-title":"Serotonin signaling is associated with lower amyloid-\u03b2 levels and plaques in transgenic mice and humans","volume":"108","author":"Cirrito","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acschemneuro.5b00135","article-title":"Serotonin: A new hope in Alzheimer\u2019s disease?","volume":"6","author":"Claeysen","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1073\/pnas.0510237103","article-title":"Serotonin 1A receptors in the living brain of Alzheimer\u2019s disease patients","volume":"103","author":"Kepe","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00213-004-2077-2","article-title":"Loss of serotonin 5-HT 2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer\u2019s disease","volume":"179","author":"Lai","year":"2005","journal-title":"Psychopharmacology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0925-4927(96)02806-5","article-title":"Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F] altanserin and positron emission tomographic imaging","volume":"68","author":"Rosier","year":"1996","journal-title":"Psychiatry Res. Neuroimaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/brain\/119.6.2001","article-title":"Presymptomatic hippocampal atrophy in Alzheimer\u2019s disease: A longitudinal MRI study","volume":"119","author":"Fox","year":"1996","journal-title":"Brain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1176\/ajp.157.1.115","article-title":"Hippocampal volume reduction in major depression","volume":"157","author":"Bremner","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1176\/appi.ajp.161.11.1957","article-title":"Hippocampal volume and depression: A meta-analysis of MRI studies","volume":"161","author":"Videbech","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5498\/wjp.v11.i6.201","article-title":"How do serotonergic psychedelics treat depression: The potential role of neuroplasticity","volume":"11","author":"Artin","year":"2021","journal-title":"World J. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biopsych.2004.04.002","article-title":"Hippocampal volume, memory, and cortisol status in major depressive disorder: Effects of treatment","volume":"56","author":"Vythilingam","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.nicl.2016.04.009","article-title":"Hippocampal volume predicts antidepressant efficacy in depressed patients without incomplete hippocampal inversion","volume":"12","author":"Colle","year":"2016","journal-title":"NeuroImage Clin."},{"key":"ref_41","first-page":"638","article-title":"The serotonin 2B receptor is required in neonatal microglia to limit neuroinflammation and sickness behavior in adulthood","volume":"69","author":"Etienne","year":"2020","journal-title":"Glia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000118256","article-title":"Alzheimer\u2019s disease and serotonin: A review","volume":"15","author":"Whitford","year":"1986","journal-title":"Neuropsychobiology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajmg.b.10068","article-title":"Depression in Alzheimer\u2019s disease: The effect of serotonin receptor gene variation","volume":"119","author":"Holmes","year":"2003","journal-title":"Am. J. Med. Genet. Part. B Neuropsychiatr. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Krebs, T.S., and Johansen, P.-\u00d8. (2013). Psychedelics and mental health: A population study. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063972"},{"key":"ref_45","first-page":"201","article-title":"Diminished glucose transport and phosphorylation in Alzheimer\u2019s disease determined by dynamic FDG-PET","volume":"37","author":"Piert","year":"1996","journal-title":"J. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/jcbfm.1991.65","article-title":"Diminished glucose transport in Alzheimer\u2019s disease: Dynamic PET studies","volume":"11","author":"Jagust","year":"1991","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1523\/JNEUROSCI.4409-12.2013","article-title":"Alzheimer\u2019s Disease Neurodegenerative Biomarkers Are Associated with Decreased Cognitive Function but Not-Amyloid in Cognitively Normal Older Individuals","volume":"33","author":"Wirth","year":"2013","journal-title":"J. Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0074-7742(02)51015-1","article-title":"Psychoactive drugs affect glucose transport and the regulation of glucose metabolism","volume":"51","author":"Dwyer","year":"2002","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"13563","DOI":"10.1074\/jbc.274.19.13563","article-title":"Serotonin (5-hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle","volume":"274","author":"Hajduch","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrn983","article-title":"Pathogenesis of Parkinson\u2019s disease: Dopamine, vesicles and \u03b1-synuclein","volume":"3","author":"Lotharius","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3389\/fnagi.2019.00175","article-title":"Dopamine and dopamine receptors in Alzheimer\u2019s disease: A systematic review and network meta-analysis","volume":"11","author":"Pan","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/bmj.282.6258.93","article-title":"Reduced dopamine-beta-hydroxylase activity in Alzheimer\u2019s disease","volume":"282","author":"Cross","year":"1981","journal-title":"Br. Med. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fnagi.2014.00252","article-title":"Is dopamine involved in Alzheimer\u2019s disease?","volume":"6","author":"Martorana","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/archneur.1991.00530230049020","article-title":"Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer\u2019s disease","volume":"48","author":"Chen","year":"1991","journal-title":"Arch. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1212\/WNL.44.12.2300","article-title":"Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer\u2019s disease: Prospective analyses from the Predictors Study","volume":"44","author":"Stern","year":"1994","journal-title":"Neurology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/archneur.1994.00540190056015","article-title":"Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer\u2019s disease","volume":"51","author":"Chui","year":"1994","journal-title":"Arch. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1755-5949.2010.00161.x","article-title":"The role of dopamine in symptoms and treatment of apathy in Alzheimer\u2019s disease","volume":"17","author":"Mitchell","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000509278","article-title":"Apathy in Alzheimer\u2019s disease correlates with the dopamine transporter level in the caudate nuclei","volume":"10","author":"Udo","year":"2020","journal-title":"Dement. Geriatr. Cogn. Disord. Extra"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0301-0082(02)00011-4","article-title":"Dopamine and the regulation of cognition and attention","volume":"67","author":"Nieoullon","year":"2002","journal-title":"Progress. Neurobiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1054-3589(08)60846-7","article-title":"The cortical dopamine system: Role in memory and cognition","volume":"42","year":"1997","journal-title":"Adv. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrn1406","article-title":"Dopamine, learning and motivation","volume":"5","author":"Wise","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/npp.2014.84","article-title":"Role of dopamine D2 receptors in human reinforcement learning","volume":"39","author":"Eisenegger","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/brain\/aws083","article-title":"Dopamine and performance in a reinforcement learning task: Evidence from Parkinson\u2019s disease","volume":"135","author":"Shiner","year":"2012","journal-title":"Brain"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"105908","DOI":"10.1016\/j.intimp.2019.105908","article-title":"The modulatory role of dopamine receptors in brain neuroinflammation","volume":"76","author":"Xia","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1523\/JNEUROSCI.0143-07.2008","article-title":"Neuroinflammation and oxidation\/nitration of \u03b1-synuclein linked to dopaminergic neurodegeneration","volume":"28","author":"Gao","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/mol.104.000299","article-title":"Cholinergic drugs for Alzheimer\u2019s disease enhance in vitro dopamine release","volume":"66","author":"Zhang","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1096\/fj.03-0770fje","article-title":"Dopamine and L-dopa disaggregate amyloid fibrils: Implications for Parkinson\u2019s and Alzheimer\u2019s disease","volume":"18","author":"Li","year":"2004","journal-title":"FASEB J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00213-022-06117-5","article-title":"Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD","volume":"239","author":"Lawn","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jns.2009.02.370","article-title":"Dendritic pathology in Alzheimer\u2019s disease","volume":"283","author":"Baloyannis","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s00213-018-4981-x","article-title":"Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Effects on cognition","volume":"235","author":"Barrett","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1162\/089892905774597191","article-title":"Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors","volume":"17","author":"Carter","year":"2005","journal-title":"J. Cogn. Neurosci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"112749","DOI":"10.1016\/j.psychres.2020.112749","article-title":"The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis","volume":"284","author":"Goldberg","year":"2020","journal-title":"Psychiatry Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Bolstridge","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Giribaldi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers","volume":"237","author":"Family","year":"2020","journal-title":"Psychopharmacology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","article-title":"Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers","volume":"86","author":"Bershad","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1017\/S0033291715002901","article-title":"The paradoxical psychological effects of lysergic acid diethylamide (LSD)","volume":"46","author":"Kaelen","year":"2016","journal-title":"Psychol. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0893-133X(01)00405-5","article-title":"A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain","volume":"26","author":"Nichols","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1523\/JNEUROSCI.23-26-08836.2003","article-title":"Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex","volume":"23","author":"Yuen","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Cini, F.A., Ornelas, I., Marcos, E., Goto-Silva, L., Nascimento, J., Ruschi, S., Salerno, J., Karmirian, K., Costa, M., and Sequerra, E. (2019). d-Lysergic acid diethylamide has major potential as a cognitive enhancer. bioRxiv, 866814.","DOI":"10.1101\/866814"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/0269881116628430","article-title":"Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide","volume":"30","author":"Speth","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000467984","article-title":"LSD-assisted psychotherapy in patients with terminal cancer","volume":"8","author":"Grof","year":"1973","journal-title":"Int. Pharmacopsychiatry"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/03602532.2019.1697283","article-title":"Adverse pharmacokinetic interactions between illicit substances and clinical drugs","volume":"52","author":"Abbott","year":"2020","journal-title":"Drug Metab. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.biopsych.2005.06.038","article-title":"Psychological and cognitive effects of long-term peyote use among Native Americans","volume":"58","author":"Halpern","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1874467211666181010154139","article-title":"Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: Clinical and forensic repercussions","volume":"12","author":"Pereira","year":"2019","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/15563650903586745","article-title":"Peyote and mescaline exposures: A 12-year review of a statewide poison center database","volume":"48","author":"Carstairs","year":"2010","journal-title":"Clin. Toxicol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0378-8741(98)00168-8","article-title":"Pharmacokinetics of Hoasca alkaloids in healthy humans","volume":"65","author":"Callaway","year":"1999","journal-title":"J. Ethnopharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3389\/fnins.2018.00536","article-title":"N, N-Dimethyltryptamine (DMT), an endogenous hallucinogen: Past, present, and future research to determine its role and function","volume":"12","author":"Barker","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1124\/dmd.111.039107","article-title":"Nonlinear pharmacokinetics of 5-methoxy-N, N-dimethyltryptamine in mice","volume":"39","author":"Shen","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.1166127","article-title":"The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator","volume":"323","author":"Fontanilla","year":"2009","journal-title":"Science"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/eji.1830251026","article-title":"Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a sigma ligand","volume":"25","author":"Bourrie","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0192-0561(95)00066-B","article-title":"The sigma ligand SR 31747 prevents the development of acute graft-versus-host disease in mice by blocking IFN-gamma and GM-CSF mRNA expression","volume":"17","author":"Carayon","year":"1995","journal-title":"Int. J. Immunopharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"srep34567","DOI":"10.1038\/srep34567","article-title":"COMPASS: A computational model to predict changes in MMSE scores 24-months after initial assessment of Alzheimer\u2019s disease","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/1573395509666131203225659","article-title":"The brain-immune-gut triangle: Innate immunity in psychiatric and neurological disorders","volume":"9","author":"Szabo","year":"2013","journal-title":"Curr. Immunol. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1021\/acschemneuro.8b00692","article-title":"Chronic, intermittent microdoses of the psychedelic N, N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents","volume":"10","author":"Cameron","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","article-title":"Ketamine use: A review","volume":"107","author":"Morgan","year":"2012","journal-title":"Addiction"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","article-title":"The effect of intravenous, intranasal, and oral ketamine\/esketamine in mood disorders: A meta-analysis","volume":"276","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: A systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0893-133X(95)00137-3","article-title":"NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers","volume":"14","author":"Malhotra","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00000542-200202000-00022","article-title":"Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers","volume":"96","author":"Pfenninger","year":"2002","journal-title":"J. Am. Soc. Anesthesiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fpsyt.2014.00149","article-title":"Long-term heavy ketamine use is associated with spatial memory impairment and altered hippocampal activation","volume":"5","author":"Morgan","year":"2014","journal-title":"Front. Psychiatry"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000087233","article-title":"Implicit and explicit memory for spatial information in Alzheimer\u2019s disease","volume":"20","author":"Kessels","year":"2005","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fnagi.2019.00186","article-title":"Ketamine: A Neglected Therapy for Alzheimer Disease","volume":"11","author":"Smalheiser","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/neurolint14020025","article-title":"The Possible Application of Ketamine in the Treatment of Depression in Alzheimer\u2019s Disease","volume":"14","author":"Masood","year":"2022","journal-title":"Neurol. Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/02791072.2020.1718250","article-title":"Psychedelic Microdosing: Prevalence and Subjective Effects","volume":"52","author":"Cameron","year":"2020","journal-title":"J. Psychoact. Drugs"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-019-0308-4","article-title":"Psychedelic microdosing benefits and challenges: An empirical codebook","volume":"16","author":"Anderson","year":"2019","journal-title":"Harm Reduct. J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/02791072.2020.1761573","article-title":"The viability of microdosing psychedelics as a strategy to enhance cognition and well-being-an early review","volume":"52","author":"Bornemann","year":"2020","journal-title":"J. Psychoact. Drugs"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/15\/12513\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:27:02Z","timestamp":1760128022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/15\/12513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":117,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["ijms241512513"],"URL":"https:\/\/doi.org\/10.3390\/ijms241512513","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]}}}